Preclinical glioma models in neuro-oncology: enhancing translational research
Serena Barachini1, Mariangela Morelli2, Orazio Santo Santonocito3
1Department of Clinical and Experimental Medicine, University of Pisa.
Purpose Of Review:
Gliomas represent approximately 25% of all primary brain and other central nervous system (CNS) tumors and 81% of malignant tumors. Unfortunately, standard treatment approaches for most CNS cancers have shown limited improvement in patient survival rates.
Recent Findings:
The current drug development process has been plagued by high failure rates, leading to a shift towards human disease models in biomedical research. Unfortunately, suitable preclinical models for brain tumors have been lacking, hampering our understanding of tumor initiation processes and the discovery of effective treatments. In this review, we will explore the diverse preclinical models employed in neuro-oncology research and their contributions to translational science.
Summary:
By utilizing a combination of these preclinical models and fostering interdisciplinary collaborations, researchers can deepen their understanding of glioma brain tumors and develop novel therapeutic strategies to combat these devastating diseases. These models offer promising prospects for personalized and efficacious treatments for these challenging malignancies. Although it is unrealistic to fully replicate the complexity of the human body in vitro, the ultimate goal should be to achieve the closest possible resemblance to the clinical context.
Insights
Developing effective brain tumor treatments is challenging due to a lack of suitable preclinical models. This review explores diverse models to advance neuro-oncology research and improve patient outcomes for gliomas.
Area of Science:
- Neuro-oncology
- Translational Science
- Biomedical Research
Background:
- Gliomas constitute a significant portion of primary brain tumors and malignant CNS cancers.
- Current treatments for CNS cancers offer limited improvements in patient survival rates.
- High failure rates in drug development necessitate improved human disease models.
Approach:
- This review explores diverse preclinical models used in neuro-oncology.
- The focus is on models that aid understanding of tumor initiation and treatment discovery.
- Contributions of these models to translational science are examined.
Key Points:
- Suitable preclinical models for brain tumors have been historically lacking.
- Advancements in preclinical models are crucial for understanding glioma biology.
- These models are vital for discovering effective therapeutic strategies.
Conclusions:
- Utilizing diverse preclinical models and interdisciplinary collaboration can deepen understanding of gliomas.
- Preclinical models offer promising avenues for developing personalized and effective glioma treatments.
- The goal is to create models that closely mimic the clinical context for enhanced translational relevance.
